NCT00478647View on ClinicalTrials.gov

Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 25, 2007

Primary Completion Date

June 26, 2009

Study Completion Date

June 26, 2009

Conditions
Gaucher Disease
Interventions
BIOLOGICAL

GA-GCB (velaglucerase alfa)

15-60 U/kg, every other week via intravenous infusion

Trial Locations (15)

10016

NYU School of Medicine, New York

30033

Emory University, Decatur

45229

Cincinatti Children's Hospital, Cincinnati

53226

Children's Hospital of Wisconsin, Milwaukee

55404

Children's of Minnesota, Minneapolis

60614

Feinberg School of Medicine, Chicago

64108

Children's Mercy Hospital and Clinic, Kansas City

77030

Texas Children's Hospital, Houston

84132

Medical Genetics/Pediatrics, Salt Lake City

90027

Regional Metabolic Center, Los Angeles

94609

Children's Hospital Oakland, Oakland

500009

Hospital Universitario Miguel Servet, Zaragoza

Unknown

Shaare Zedek Medical Center, Jerusalem

Children's Memorial Health Institute, Warsaw

The Royal Free Hospital, London

Sponsors

Lead Sponsor

Shire
All Listed Sponsors
lead

Shire

INDUSTRY

NCT00478647 - Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase | Biotech Hunter | Biotech Hunter